Compare ADEA & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADEA | GRDN |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | 3400 |
| Industry | Computer Software: Prepackaged Software | Retail-Drug Stores and Proprietary Stores |
| Sector | Technology | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2020 | N/A |
| Metric | ADEA | GRDN |
|---|---|---|
| Price | $19.86 | $31.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $26.50 | ★ $33.33 |
| AVG Volume (30 Days) | ★ 873.1K | 146.9K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $443,386,000.00 | N/A |
| Revenue This Year | N/A | $19.50 |
| Revenue Next Year | $7.90 | N/A |
| P/E Ratio | ★ $21.18 | $117.77 |
| Revenue Growth | ★ 17.91 | N/A |
| 52 Week Low | $10.59 | $18.01 |
| 52 Week High | $21.07 | $37.43 |
| Indicator | ADEA | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 45.25 |
| Support Level | $16.21 | $31.82 |
| Resistance Level | $19.97 | $32.01 |
| Average True Range (ATR) | 0.90 | 1.28 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 67.82 | 15.28 |
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.